Background: Patients with diabetes mellitus and IGT have a high risk for cardiovascular events. It is tempting to speculate that these patients are often first seen by cardiologists. Design: This cross-sectional study investigates the diabetes prevalence in cardiology care units and the correlated metabolic conditions as assessed by several circulating biomarkers. Methods: Patients aged 55 or older with suspected or overt coronary heart disease were eligible for trial participation. Fasting blood samples were drawn from patients to determine HOMA score, glycaemic and lipid profile, and several risk biomarkers. An OGTT was performed in patients without known diabetes. Results: We enrolled 530 patients (181 male, 349 female, mean age, 68±7 years) in this study from 22 German cardiology centres; 156 patients (29.4%) had known diabetes and OGTT revealed that 184 patients (34.7%) had no diabetes, 106 patients (20.0%) had IGT or IFG and 84 patients (15.9%) were newly diagnosed with diabetes. Increased cardiovascular risk as reflected by increased hsCRP, ICAM and MMP-9 values was observed in diabetes patients. A higher cardiovascular biomarkers risk profile was seen in the IGT/IFG cohort. Conclusions: This study confirms the observation that one third of patients of a cardiologic care unit suffer from impaired glucose regulation. Furthermore, the cardiology patients with previously unknown glucose homeostasis abnormalities had a higher prevalence of macrovacular disease and an impaired biomarker risk profile. This study underlines the importance of joint treatment efforts by cardiologists in concert with diabetologists for treatment of this patient group at high risk for cardiovascular events.
Introduction
Cardiovascular diseases (CVD), e.g. coronary heart disease (CHD) such as myocardial infarction, are the major complications in patients with type 2 diabetes (T2D) and are the major cause of morbidity and mortality in this population. People with diabetes suffer from a two-to four-fold increased risk of incident CHD or fatal CVD compared with patients without diabetes. Accordingly, CVD are the major contributor to CVD-related costs in patients with diabetes. Early detection of diabetes is therefore considered a cost-saving approach, together with the possibility for secondary prevention and patient empowerment after diagnosis. 1 The relation of CVD and metabolic imbalance lays in the association of metabolic (glucose, lipids) disorders with factors are increased. This imbalance leads to an impairment of endothelium-dependent vasodilatation. If ED persists over an extended period of time, reactive thickening of smooth muscle cells on the basis of low-grade inflammation of the arterial wall may follow. This leads to the first stages of atherosclerotic changes which can result in macrovascular complications such as CHD.
This epidemiological study aims to assess the prevalence of abnormal glucose metabolism, such as impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and known and newly diagnosed overt diabetes mellitus in patients with suspected or established CHD. It therefore contributes to answering the question of whether screening for diabetes and IGT is reasonable in patients with CHD.
Material and methods

Study design
The study was designed as a cross-sectional epidemiologic study in cardiology centres and practices throughout Germany. The trial was approved by an institutional review board and conducted following the regulations of Good Clinical Practice. Prior to any study procedure, a signed informed consent was obtained from each patient.
Patient population
Male and female patients aged 55 or older with suspected or overt CHD undergoing elective coronary angiography were eligible for study participation. Patients with acute gastrointestinal infection, acute feverish illness, suspected of medication, drug or alcohol abuse or without legal capacity were excluded from the trial. Prevalence of macrovascular disease (myocardial infarction, stroke, angina pectoris, peripheral or coronary artery disease) was assessed by a standardised questionnaire.
Study visit
The collection of data and of the blood samples was performed in one day but before angiography. The patient was in an overnight fasting state from the evening onward before they arrived at the study site. Blood was drawn for the measurement of the efficacy laboratory parameters from all patients to determine several risk biomarkers. Body weight, height, waist and hip circumference and blood pressure were recorded using standardised methods. In all patients without known diabetes or without confirmed random plasma glucose at admission equal or above 200 mg/dl, a 75 g oral glucose tolerance test (OGTT) was performed under standardised fasting conditions. T2D was diagnosed according to current international guidelines.
Laboratory procedures
All laboratory variables were determined in the central laboratory at the Institute for Clinical Research and Development (IKFE) by using standard methods according to the corresponding manufacturer's instructions. Plasma glucose was determined enzymatically (SuperGL, RLT, Möhnesee-Delecke, Germany), high-sensitive C-reactive protein with an enzyme immuno assay (MP Biomedicals, LLC, Eschwege, Germany), and HbA1c was measured colourimetrically with an automatic glycohaemoglobin analyser (AdamsTM A1c, HA-8160 Kit, Menarini Diagnostics, Neuss, Germany). Lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol) were measured by photometry. Standard enzyme-linked immunosorbent assays (ELISAs) supplied by R&D systems (Minneapolis, USA) were used to quantify monocyte chemoattractant protein-1 (MCP 1), interleukin-6 (IL-6), matrix metallo proteinase-9 (MMP-9), soluble CD 40 ligand (sCD40L), soluble intracellular adhesion molecule (sICAM), soluble vascular adhesion molecule (sVCAM), and E-selectin. Insulin and intact proinsulin were determined by ELISA (Metascreen, TecoMedical, Sisslach, Switzerland).
Data analysis
Statistical analysis was performed using standard descriptive statistics and appropriate parametrical and non-parametrical tests. The means of the variables were compared using two-sided Student's t-test. p-values < 0.05 were considered statistically significant.
Results
In total, 530 patients were enrolled in this study from 22 cardiology centres throughout Germany. The study cohort consisted of 181 male and 349 female patients with a mean age (± SD) of 68±7 years; 156 patients (29.4%) had known diabetes and 184 patients (34.7%) had no diabetes; 106 patients (20.0%) suffered from IGT or IFG whereas 84 patients (15.9%) were newly diagnosed for diabetes. Within these groups the patients were equally distributed according to age, gender and intake of anti-hypertensive drugs with moderate but insignificantly reduced values in the group of patients without diabetes (age: no diabetes 66.9±7.2 years, known diabetes 68.5±7.4 years, IGT/IFG 68.7±7.3 years, newly diagnosed diabetes 68.3±7.7 years; gender: no diabetes 115 females (62.5%) and 69 males (37.5%), known diabetes 101 females (64.7%) and 55 males (35.3%), IGT/IFG 78 females (73.6%) and 28 males (26.4%), new diabetes diagnosis 55 females (65.5%) and 29 males (34.5%); patients treated with anti-hypertensives: no diabetes 116 (63.0%), known diabetes 132 (84.6%), IGT/IFG 91 (86%), new diabetes diagnosis 68 (81.0%)). Table 1 shows the higher prevalence of a history of macrovascular events in patients with abnormalities in glycaemic homeostasis compared with patients without diabetes. It is noteworthy that only the IFG/IGT group showed significantly increased occurrence of previous macrovascular events. This was not the case in diabetic patients, but this result might be traced back to the total number of enrolled patients. Risk marker data from patients with abnormalities in glucose homeostasis were then compared with the data from patients without diabetes. Table 2 displays the significant differences of several markers between the groups. Insulin resistance as assessed by homeostasis model assessment (HOMA) score was significantly lower in the group without diabetes. The glycaemic profile (HbA1c, fasting blood glucose) showed the expected significant deterioration in all groups compared with the 'No diabetes' cohort. The other parameters are considered to be cardiovascular risk markers (MMP-9, MCP-1, ICAM, VCAM, lipids) or markers of chronic inflammation (hsCRP, IL-6). The cardiovascular risk is increased in both groups of patients with diabetes displayed by significant augmentation of hsCRP, adhesion molecules and MMP-9. It is of interest that patients with IGT/IFG have also a higher risk according to the pattern of the surrogate markers MMP-9, ICAM, VCAM, sCD40L, MCP-1, E-selectin and IL-6.
Discussion
The prevalence of diabetes is projected to rise substantially and to a greater extent than estimated previously. 2 It is far from demonstrated that reducing plasma glucose prospectively translates into reduced cardiovascular morbidity/ mortality. Targeting the common underlying causes of glycaemic elevation and CHD seems on the other hand to have a substantial rationale. 3 Together with the data that complications, in particular concerning macrovascular events, account for the majority of deaths among the diabetes population, 4 it is clear that early diagnosis and treatment of metabolic abnormalities can be a powerful tool for health care systems to save lives and, additionally, to save costs as a favourable secondary objective. 1 Recently, the European Heart Survey, which included 110 centres in 25 countries, demonstrated that in patients with manifest CHD, normoglycaemia (49%) is nearly as common as abnormal glucose regulation (51%). 5 In a study including more than 8,800 patients receiving a coronary artery bypass graft (CABG), 28.2% of patients had diagnosed T2D, 23.3% had IGT and 5.2% had undiagnosed T2D. This latter group was characterised by a higher morbidity and mortality in the peri-and postoperative period. 6 European epidemiological studies have indicated that about 7 Nearly half of them (8.2%) were previously undiagnosed cases. The fact that hypertension as well as dyslipidemic disorders in this group is as common as in the group of diagnosed T2D shows an increased risk of cardiovascular events even if the disease has not become obvious to the patients in the form of symptoms. Another 16% showed impaired glucose tolerance, which further increases the number of patients with an abnormal glucose metabolism. In the MONICA Augsburg myocardial infarction (MI) registry, also a high prevalence of undiagnosed diabetes (12%) and IGT (27%) was observed in long-term MI survivors. 8 The decreased survival of diabetic individuals after MI has been attributed to a more severe atherosclerosis, higher incidence of cardiac failure, cardiomyopathy, autonomic neuropathy and an increased risk of arrhythmias. 9 Despite a poor prognosis in such cases, elevated blood glucose levels are often poorly recognised or they are often not attributed to the diagnosis of diabetes. A high prevalence of undiagnosed diabetes was reported in patients scheduled for coronary angiography in a German centre. 10 Among 3,266 high-risk patients, as many subjects with undiagnosed diabetes (17.9%) as patients with known diabetes (17.0%) were observed; representative data of the prevalence of prediabetes and diabetes in a well-defined population at high risk for macrovascular complications are lacking for Germany. The European Society for Cardiology and the European Association for the Study of Diabetes have recommended taking the close relation of diabetes and CVD into account in diagnostic procedures. 11 They provide guidelines that diabetologists should consider macrovascular complications more attentively, and for cardiologists to consider glycaemic control in their patient population. In order to assess the prevalence of abnormal glucose metabolism in a cardiologic patient cohort, this epidemiological study investigated IGT, IFG, known and newly diagnosed diabetes mellitus in patients with suspected or established CHD.
The study confirms the observation that nearly one-third of subjects attending a cardiologic care unit for coronary angiography/procedure suffer from known impaired glucose regulation. Looking at patients of primary care physicians, 16% are at increased cardiovascular risk due to diabetes or impaired fasting glucose. 12 A number of discrete CVD risk factors are known which may cluster in individuals but may not all necessarily be present. 13 They include markers of glucose regulation, obesity, hypertension, vascular inflammation, coagulation, dyslipidaemia, endothelial dysfunction and microalbuminuria. This study investigates thrombotic markers (MMP-9, sCD40L, E-selectin), parameters associated with endothelial dysfunction (ICAM, VCAM), the lipid profile and markers of chronic vascular inflammation (hsCRP, MCP-1, IL-6). As expected, the diabetes patients show increased values of hsCRP, MMP-9 and adhesion molecules. These biological markers are involved with the pathophysiology of atherosclerosis, one of the major contributors to CVD. Consistently, these markers are considered predictors for macrovascular risk.
It is of special interest that patients with IGT/IFG also have a higher cardiovascular risk according to the pattern of the investigated markers. There is growing evidence that abnormalities in glucose homeostasis contribute to an increased cardiovascular risk. However, IGT/IFG are not suitable for short-term risk assessment. 14 The cardiovascular risk is considered to be driven by the existence of multiple metabolic comorbidities rather than the hyperglycaemia alone. 15 This study confirms that identification of a cluster of metabolic abnormalities should be considered more carefully for CVD prevention. Although isolated IFG or IGT was not associated with a more adverse CVD risk profile applying the new American Diabetes Association (ADA) criteria, 16 the mortality risk rises by more than two-fold after conversion from IFG to manifest diabetes. 17 Thus, the additional information about the biomedical markers as outlined in this study might be a powerful tool to classify the cardiovascular risk of patients with IFG. In particular, overweight or obese patients with IFG/IGT strictly need intensive lifestyle intervention and medical care by annual OGTT according to the recommendations of Australian societies. 18 Treatment regimens for patients with IGT/IFG should therefore be optimised, e.g. resembling a regular antidiabetic therapy, in order to prevent manifest diabetes or even prolong the time to develop diabetes and the related complications.
Finally, it needs to be considered that even amongst the normoglycaemic patients, there is an increased risk of atherosclerosis related to the abnormal phenotype associated with insulin resistance and/or the metabolic syndrome. In this study, normoglycaemic insulin resistance, as assessed by the homeostatic model assessment -insulin resistance (HOMA-IR) score or elevated fasting morning intact proinsulin concentrations, 19 was present in one-sixth of the entire patient cohort. They present with normal metabolic conditions. We have been able to demonstrate that this particular patient cohort with normoglycaemic vascular insulin resistance (also referred to as 'cardiodiabetes' or 'angiodiabetes') may be considered for insulin sensitisation, using, e.g., lifestyle intervention and/or drug therapy such as glitazones. [20] [21] [22] The patients visiting cardiology specialists with previously unknown glucose homeostasis abnormalities had a higher prevalence of macrovascular disease and an impaired laboratory risk marker profile. Accordingly, the risk of new myocardial infarction was highest in patients with diabetes. 23 The hazard ratio did not increase considerably if known heart failure is added in this calculation. Recently, Wallander et al. 24 reported that dysglycaemia after acute myocardial infarction reflects a stable glucose abnormality rather than a stress epiphenomenon. They consider disturbances in glucose regulation a common feature of patients with acute MI but without previously known diabetes. The underlying abnormalities leading to abnormal glucose homeostasis may represent a major modifiable component of subsequent cardiovascular risk in patients with acute MI. 25 This study confirms the importance of early diagnosis and appropriate treatment of diabetes patients suffering from macrovascular disease. A pattern of cardiovascular surrogate risk markers as assessed in our study may help the cardiologist to critically distinguish high-risk individuals who need careful glucose metabolism tailored treatment.
In conclusion, 85% of the patients visiting cardiology centres in Germany suffer from known or unknown diabetes, IGT, or normoglycaemic vascular insulin resistance (cardiodiabetes). This finding underlines the importance of joint treatment efforts from both disciplines when treating this patient group at high risk for cardiovascular mortality.
